Xconomy: Alkermes News, Articles and Opinions

“alkermes” Archives

Entry	Author	Date	Location
The Placebo Effect Is Hobbling New Psychiatric Drugs. What Can Stop It?	Alex Lash	10/10/19	National
Biotech Roundup: Vaping Toll Rises, NASH News, Akcea Shakeup & More	Frank Vinluan	09/27/19	National
Biogen, Taking Its Crisis “Seriously,” Keeps Focus on Neuroscience	Ben Fidler	04/24/19	Boston
Bio Roundup: New CRISPR Feud, A NY Splash, Pharma vs. Congress & More	Ben Fidler	02/08/19	National
FDA Rejects Alkermes Depression Drug, Asks for More Clinical Data	Frank Vinluan	02/01/19	Boston
Alkermes Schizophrenia Drug Heads To FDA, But Questions Linger	Ben Fidler	11/29/18	Boston
Expansion Therapeutics Hires Elliot Enrich as CMO	Sarah de Crescenzo	11/13/18	San Diego
Bio Roundup: Depression Drug Dashed, Peek at ASH, CRISPR Worry & More	Alex Lash	11/02/18	National
Alkermes Depression Drug Faces Long Odds After FDA Advisors Say No	Ben Fidler	11/01/18	Boston
FDA Blasts Data, Trial Design For Alkermes Depression Drug	Ben Fidler	10/30/18	Boston
With $1.6B Armo Buy, Eli Lilly Is the Latest to Bet Big on Cytokines	Frank Vinluan	05/10/18	Indiana
Bio Roundup: Hope for Lungs, Bradner’s Complaint, FDA Nods & More	Alex Lash	04/20/18	National
Alkermes Depression Drug Review Goes Ahead After FDA About-Face	Corie Lok	04/16/18	Boston
Bio Roundup: Ex-Kiters Say Allo, NASH Cash & Data, Alkermes No & More	Alex Lash	04/06/18	National
FDA Refuses Review of Alkermes Depression Drug, Wants More Trials	Frank Vinluan	04/02/18	Boston
Sage Shares Soar Again As Depression Drug Hits Mark in Phase 2 Test	Ben Fidler	12/07/17	Boston
15 For ’18: Key Clinical Data to Watch For Next Year (Part 2)	Alex Lash	12/06/17	National
Bio Roundup: Migraine Data, Cancer Drug Combos, Azar Hearing & More	Frank Vinluan	12/01/17	National
Bio Roundup: Barron Joins GSK, Sage Bounces Back, Valeant Dumps Addyi	Ben Fidler	11/10/17	National
Bio Roundup: Drug Price Debates, NY Bio Blooms & CEOs Take Social Stand	Frank Vinluan	08/25/17	National
Side Effect Weighs on Early Results for Alkermes’ Schizophrenia Drug	Frank Vinluan	06/29/17	Boston
Bio Roundup: Trumpcare Is Mean, SCOTUS Says Go, Merck’s Myeloma No	Ben Fidler	06/16/17	National
Stifling Immigration Is “Retrograde”: Highlights From “What’s Hot”	Ben Fidler	05/17/17	Boston
On Tap For “What’s Hot” on May 11: Opioid Crisis, Immigration & More	Ben Fidler	04/13/17	Boston
Check Out What’s Hot in Boston Biotech on May 11: Saver Rate Ends Today	Ashley Gentile	04/06/17	Boston
Alkermes Eyes FDA Nod After Retooled Study Yields Desired Results	David Holley	10/20/16	Boston
BlackThorn Emerges With $40M, New Weapons Against Neuro Disorders	Ben Fidler	10/20/16	San Francisco
Intra-Cellular Shares Sink As Schizophrenia Drug Flunks Final Test	Ben Fidler	09/28/16	New York
Caveats But No “Quicksand” In Sage’s Positive Postpartum Trial Data	Alex Lash	07/12/16	Boston
Biotech Roundup: Duchenne Delay, Forum’s Fate, Califf, Ionis & More	Ben Fidler	05/27/16	National
Page 1 of 7	next page »